Epcoritamab NCT06287398 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 2

Clinical phase

Recruiting

Recruitment status

not reported

Planned enrollment

2026-11-01

Primary-completion proxy

Executive view

NCT06287398 evaluates Epcoritamab in High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. The disclosed sponsor is Australasian Leukaemia & Lymphoma Group, the design is Interventional, and the geographic footprint is Australia. The first listed primary endpoint is Event-free survival (EFS), assessed over 12 months.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06287398 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements landscape. Drug & Asset MCP drug_fetch was queried for Epcoritamab, while Company & Deal Intelligence MCP organization_fetch was queried for Australasian Leukaemia & Lymphoma Group.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT06287398	Epcoritamab	Phase 2 / Recruiting	Australasian Leukaemia & Lymphoma Group	Australia	Event-free survival (EFS) 12 months	2026-11-01
NCT06484920	Tretinoin	Phase 2 / Recruiting	Indiana University	United States	Incidence of Adverse Events from start of treatment through 90 days safety follow-up visit	2027-12-01
NCT06486051	Fludarabine Phosphate	Phase 2 / Recruiting	The Malaghan Institute of Medical Research	New Zealand	Complete response (CR) rate per Investigator assessment 3 months after atlacabtagene autoleucel administration	2027-06-30
NCT06470438	JNJ-88998377	Phase 1 / Active, not recruiting	Janssen Research & Development LLC	South Korea, Japan, China, Turkey, Taiwan Province, Poland, Italy	Parts A and B: Number of Participants with Adverse Events (AEs) Upto 3 years 4 months	2027-10-29
NCT06468943	Polatuzumab Vedotin-Piiq	Phase 2 / Enrolling by invitation	The First Affiliated Hospital of Soochow University	China	Progression-free Survival（PFS） From date of enrollment until the date follow up for 2 years after th…	2026-05-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT06287398 is a Phase 2, recruiting study with not reported planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Event-free survival (EFS)” over “12 months.” The retrieved endpoint description is: Time to event outcome measured in days from commencement of each treatment subset (salvage chemotherapy and Epcoritamab/ASCT/ Epcoritamab re-treatment) to date of first to occur out of reduced partial response (PR) after C2, commencement of non-protocolised cancer treatment, progression or death from any cause..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. These records do not establish direct evidence for NCT06287398 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Epcoritamab is indexed as Bispecific T-cell Engager (BiTE) with CD20 x CD3 biology and a global stage of Approved. The asset profile lists Genmab A/S as an originator or developer.

Australasian Leukaemia & Lymphoma Group is indexed in an unreported country with the website https://www.allg.org.au. Australasian Leukaemia & Lymphoma Group is a cancer research center that specializes in clinical trials and treatments for blood cancer. The record lists an unreported number of development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Epcoritamab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT06287398
Protocol source: https://clinicaltrials.gov/study/NCT06287398
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 October 2026.

Epcoritamab in High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Event-free survival (EFS) and 2026-11-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP